We are a tech start-up based in Stockholm, Sweden. Akira Science provides pliable 3D-printed scaffolds for soft tissue engineering. Our customized scaffolds are the result of the combined expertise in degradable polymer synthesis, mechanical simulation and cell-material interaction.
Today, there is a solid clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, today’s standard replacement joints don’t last forever. The limited lifespan of common replacement joints limits their use to patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options.
Our company, Nanochon, is developing an implant that is designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
Today, Samsara cells and tissues are enabling cutting edge research in the study of human biology and disease. In the hands of our partners and customers, our cells are contributing to the advancement of new tissue models, helping researchers identify promising new drugs that may treat life-threatening diseases, and breaking new ground in regenerative medicine.
The Foundation for Research and Science Development was established in 2009 and has the status of a Scientific Unit entered into the POLON MNiSW (Ministry of Science and Higher Education) system. The organization deals mainly with educational and research activities in the field of medical and biochemical sciences. It was created out of passion and the will to change the reality that surrounds us. The inspiration for establishing the Foundation was and is the scientific activity of Michał Wszoła MD, PhD., surgeon, transplantologist and, most of all, a dedicated doctor.
Founded in 2016, Qrons is a publicly traded, preclinical biotechnology company, developing advanced cell-based solutions to combat neurological injuries. While we are laser-focused on traumatic brain injury (TBI), our technology could potentially treat a wide range of neurodegenerative diseases.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time.
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.
SE3D.com is an EdTech startup, funded by the National Science Foundation, specializing in science education courseware and desktop 3D bioprinters for K9-14. Our unique curriculum and equipment is designed to prepare and propel the next generation of biomedical scientists, engineers and innovators.
CollPlant Biotechnologies is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and the development of medical aesthetics products. CollPlant’s revolutionary products, including its BioInks, are based on its proprietary recombinant human collagen (rhCollagen) which is produced in genetically engineered tobacco plants. CollPlant recently entered a licensing deal worth $44 million plus royalties with United Therapeutics, a $4 billion company, for its BioInk technology to manufacture 3D bioprinted lungs for transplantation. In the medical aesthetics market, CollPlant is developing 3D bioprinted breast implants for regeneration of breast tissue, and a dermal filler product line for the $4.5 billion global dermal filler market. CollPlant is currently in talks for potential strategic partnerships with big pharma companies for its BioInk and medical aesthetics technologies.Collplant is a public company listed on the Tel Aviv Stock Exchange and on the OTCQX
The Institute for Bioengineering of Catalonia (IBEC) conducts excellent interdisciplinary research at the frontiers of engineering and life sciences in order to generate new knowledge by putting together fields like nanomedicine, biophysics, biotechnology, tissue engineering and the applications of health information technology.
MEDPRIN BIOTECH is a high-tech enterprise co-founded by outstanding biomedical scientists in September 2008, specialized in R & D, production and sales of regenerative medicine materials and regenerative implantable medical devices. MEDPRIN aims to become global leader in the field of implantable medical devices, relying on amazing capacity to provide excellent products for the patients worldwide based on biological 3D printing technology and nano-bionics technology, so MEDPRIN will accurately and efficiently manufacture more new implantable medical devices for human tissue recovery, replacement and regeneration, in accordance with the enterprise cultures featured in "innovation, cooperation and mutual love" and the quality policy to play a leading role in science & technology capacity and quality and constantly keep sound integrity to save more lives.
Our vision is to discover the brilliant idea in search of realization. We advocate the new formulation, the inspired concept, and the big idea that might change our patients' lives. We ask ourselves "what if?" and "can you imagine?" And you know what? We can.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have five approved products on the market today and are relentless in our pursuit of “medicines for life”®.
UT is recognized as one of the Top 10 Corporate Citizens in the field of U.S. drug manufacturing